September 27, 2023 12:40 PM EDT

FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshop

Lia DeGroot

The FDA is reopening the comment period on its discussion paper on using artificial intelligence in drug development, coinciding with a two-day workshop on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshop

Lia DeGroot

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshop